{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T10:00:22Z","timestamp":1794650422191,"version":"4.9.1"},"reference-count":66,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"12","license":[{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Hematopoietic cell transplantation (HCT) is the only potentially curative treatment option for many patients with hematologic malignancies. While HCT outcomes have improved drastically over the years, patients and clinicians continue to face numerous survivorship challenges, such as relapse, graft-versus-host disease, and secondary malignancies. Recent literature suggests that clonal hematopoiesis (CH), the presence of a recurrent somatic mutation in hematopoietic cells, in HCT patients or donors may be associated with outcomes in autologous and allogeneic HCT. Herein, we perform a review of the literature and summarize reported associations between CH and clinical outcomes in HCT. For commonly reported outcomes, we used meta-analysis methods to provide estimates of effect sizes when combining results. A total of 32 articles with relevant and independent contributions were included, covering both autologous (N=19) and allogeneic (N=13) HCT. The articles report variable risk for developing outcomes according to CH characteristics, patient disease status, and method of HCT. Using meta-analysis of available results, HCT outcomes with statistically significant effects by CH status include therapy-related myeloid neoplasms (odds ratio =3.65; 95% confidence interval [CI]: 2.18-6.10) and overall survival (hazard ratio [HR]=1.38; 95% CI: 1.20-1.58) in autologous HCT and relapse (HR=0.80; 95% CI: 0.68-0.94) in allogeneic HCT. However, heterogeneity, biases, and limitations in the literature provide challenges for informing the translation of CH to clinical decision- making. We conclude with a call to action and discussion of next steps to build upon the current literature and provide granularity to the true clinical impact of CH in the setting of HCT.<\/jats:p>","DOI":"10.3324\/haematol.2024.285392","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T04:20:05Z","timestamp":1718857205000},"page":"3952-3964","source":"Crossref","is-referenced-by-count":7,"title":["Clinical impact of clonal hematopoiesis in hematopoietic cell transplantation: a review, meta-analysis, and call to action"],"prefix":"10.3324","volume":"109","author":[{"given":"Nancy","family":"Gillis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Ebied","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary J.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Pidala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,6,20]]},"reference":[{"key":"69745","doi-asserted-by":"crossref","unstructured":"Koreth J, Pidala J, Perez WS. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol. 2013; 31(21):2662-2670.","DOI":"10.1200\/JCO.2012.46.8652"},{"key":"69746","doi-asserted-by":"crossref","unstructured":"Sekeres MA, Guyatt G, Abel G. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Adv. 2020; 4(15):3528-3549.","DOI":"10.1182\/bloodadvances.2020001920"},{"key":"69747","doi-asserted-by":"crossref","unstructured":"de Witte T, Bowen D, Robin M. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017; 129(13):1753-1762.","DOI":"10.1182\/blood-2016-06-724500"},{"key":"69748","doi-asserted-by":"crossref","unstructured":"Hashmi SK, Lee SJ, Savani BN. ASBMT Practice Guidelines Committee survey on long-term follow-up clinics for hematopoietic cell transplant survivors. Biol Blood Marrow Transplant. 2018; 24(6):1119-1124.","DOI":"10.1016\/j.bbmt.2018.03.023"},{"key":"69749","doi-asserted-by":"crossref","unstructured":"Steensma DP, Bejar R, Jaiswal S. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015; 126(1):9-16.","DOI":"10.1182\/blood-2015-03-631747"},{"key":"69750","doi-asserted-by":"crossref","unstructured":"Jaiswal S, Fontanillas P, Flannick J. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014; 371(26):2488-2498.","DOI":"10.1056\/NEJMoa1408617"},{"key":"69751","doi-asserted-by":"crossref","unstructured":"Genovese G, Kahler AK, Handsaker RE. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371(26):2477-2487.","DOI":"10.1056\/NEJMoa1409405"},{"key":"69752","doi-asserted-by":"crossref","unstructured":"Fabre MA, de Almeida JG, Fiorillo E. The longitudinal dynamics and natural history of clonal haematopoiesis. Nature. 2022; 606(7913):335-342.","DOI":"10.1038\/s41586-022-04785-z"},{"key":"69753","doi-asserted-by":"crossref","unstructured":"Young AL, Challen GA, Birmann BM, Druley TE. Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat Commun. 2016; 7:12484.","DOI":"10.1038\/ncomms12484"},{"key":"69754","doi-asserted-by":"crossref","unstructured":"Steensma DP, Ebert BL. Clonal hematopoiesis as a model for premalignant changes during aging. Exp Hematol. 2020; 83:48-56.","DOI":"10.1016\/j.exphem.2019.12.001"},{"key":"69755","doi-asserted-by":"crossref","unstructured":"Wong WJ, Emdin C, Bick AG. Clonal haematopoiesis and risk of chronic liver disease. Nature. 2023; 616(7958):747-754.","DOI":"10.1038\/s41586-023-05857-4"},{"key":"69756","doi-asserted-by":"crossref","unstructured":"Bolton KL, Koh Y, Foote MB. Clonal hematopoiesis is associated with risk of severe Covid-19. Nat Commun. 2021; 12(1):5975.","DOI":"10.1038\/s41467-021-26138-6"},{"key":"69757","doi-asserted-by":"crossref","unstructured":"Jaiswal S, Natarajan P, Silver AJ. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017; 377(2):111-121.","DOI":"10.1056\/NEJMoa1701719"},{"key":"69758","doi-asserted-by":"crossref","unstructured":"Coombs CC, Zehir A, Devlin SM. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell. 2017; 21(3):374-382.","DOI":"10.1016\/j.stem.2017.07.010"},{"key":"69759","doi-asserted-by":"crossref","unstructured":"Mach-Pascual S, Legare RD, Lu D. Predictive value of clonality assays in patients with non-Hodgkin\u2019s lymphoma undergoing autologous bone marrow transplant: a single institution study. Blood. 1998; 91(12):4496-4503.","DOI":"10.1182\/blood.V91.12.4496.412k14_4496_4503"},{"key":"69760","doi-asserted-by":"crossref","unstructured":"Heini AD, Porret N, Zenhaeusern R, Winkler A, Bacher U, Pabst T. Clonal hematopoiesis after autologous stem cell transplantation does not confer adverse prognosis in patients with AML. Cancers (Basel). 2021; 13(13):3190.","DOI":"10.3390\/cancers13133190"},{"key":"69761","doi-asserted-by":"crossref","unstructured":"Barlogie B, Tricot G, Haessler J. Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989. Blood. 2008; 111(1):94-100.","DOI":"10.1182\/blood-2007-06-097444"},{"key":"69762","doi-asserted-by":"crossref","unstructured":"Gifford G, Hesson L, Wong JWH. Poor mobilization of autologous CD34(+) peripheral blood stem cells in haematology patients undergoing autologous stem cell transplantation is associated with the presence of variants in genes implicated in clonal haematopoiesis of indeterminant potential. Br J Haematol. 2021; 193(4):841-844.","DOI":"10.1111\/bjh.17316"},{"key":"69763","doi-asserted-by":"crossref","unstructured":"Gibson CJ, Lindsley RC, Tchekmedyian V. Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma. J Clin Oncol. 2017; 35(14):1598-1605.","DOI":"10.1200\/JCO.2016.71.6712"},{"key":"69764","doi-asserted-by":"crossref","unstructured":"Mouhieddine TH, Sperling AS, Redd R. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020; 11(1):2996.","DOI":"10.1038\/s41467-020-16805-5"},{"key":"69765","doi-asserted-by":"crossref","unstructured":"Hazenberg CLE, de Graaf AO, Mulder R. Clonal hematopoiesis in patients with stem cell mobilization failure: a nested case-control study. Blood Adv. 2023; 7(7):1269-1278.","DOI":"10.1182\/bloodadvances.2022007497"},{"key":"69766","doi-asserted-by":"crossref","unstructured":"Stelmach P, Richter S, Sauer S. Clonal hematopoiesis with DNMT3A and PPM1D mutations impairs regeneration in autologous stem cell transplant recipients. Haematologica. 2023; 108(12):3308-3320.","DOI":"10.3324\/haematol.2023.282992"},{"key":"69767","doi-asserted-by":"crossref","unstructured":"Ortmann CA, Dorsheimer L, Abou-El-Ardat K. Functional dominance of CHIP-mutated hematopoietic stem cells in patients undergoing autologous transplantation. Cell Rep. 2019; 27(7):2022-2028.","DOI":"10.1016\/j.celrep.2019.04.064"},{"key":"69768","doi-asserted-by":"crossref","unstructured":"Lackraj T, Ben Barouch S, Medeiros JJF. Clinical significance of clonal hematopoiesis in the setting of autologous stem cell transplantation for lymphoma. Am J Hematol. 2022; 97(12):1538-1547.","DOI":"10.1002\/ajh.26726"},{"key":"69769","doi-asserted-by":"crossref","unstructured":"Bernstein SH, Nademanee AP, Vose JM. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. Blood. 1998; 91(9):3509-3517.","DOI":"10.1182\/blood.V91.9.3509.3509_3509_3517"},{"key":"69770","doi-asserted-by":"crossref","unstructured":"Wallington-Beddoe CT, Gottlieb DJ, Garvin F, Antonenas V, Sartor MM. Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2009; 15(11):1386-1393.","DOI":"10.1016\/j.bbmt.2009.06.018"},{"key":"69771","doi-asserted-by":"crossref","unstructured":"Okada Y, Kimura F, Kurita N. Adverse impact of delay of platelet recovery after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma and multiple myeloma. Cytotherapy. 2023; 25(11):1212-1219.","DOI":"10.1016\/j.jcyt.2023.05.015"},{"key":"69772","doi-asserted-by":"crossref","unstructured":"Li N, Liang L, Xiang P, Wang Y, Liu L, Fang B. Clonal haematopoiesis of indeterminate potential predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma. Br J Haematol. 2023; 201(3):577-580.","DOI":"10.1111\/bjh.18716"},{"key":"69773","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian RP. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022; 140(11):1200-1228.","DOI":"10.1182\/blood.2022015850"},{"key":"69774","doi-asserted-by":"crossref","unstructured":"McNerney ME, Godley LA, Le Beau MM. Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer. 2017; 17(9):513-527.","DOI":"10.1038\/nrc.2017.60"},{"key":"69775","doi-asserted-by":"crossref","unstructured":"Wong TN, Ramsingh G, Young AL. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature. 2015; 518(7540):552-555.","DOI":"10.1038\/nature13968"},{"key":"69776","doi-asserted-by":"crossref","unstructured":"Gillis NK, Ball M, Zhang Q. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. Lancet Oncol. 2017; 18(1):112-121.","DOI":"10.1016\/S1470-2045(16)30627-1"},{"key":"69777","doi-asserted-by":"crossref","unstructured":"Takahashi K, Wang F, Kantarjian H. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol. 2017; 18(1):100-111.","DOI":"10.1016\/S1470-2045(16)30626-X"},{"key":"69778","doi-asserted-by":"crossref","unstructured":"Husby S, Favero F, Nielsen C. Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study. Leukemia. 2020; 34(12):3256-3268.","DOI":"10.1038\/s41375-020-0795-z"},{"key":"69779","doi-asserted-by":"crossref","unstructured":"Yan C, Richard MA, Gibson CJ. Clonal hematopoiesis and therapy-related myeloid neoplasms after autologous transplant for Hodgkin lymphoma. J Clin Oncol. 2024; 42(20):2415-2424.","DOI":"10.1200\/JCO.23.02547"},{"key":"69780","doi-asserted-by":"crossref","unstructured":"Wudhikarn K, Padrnos L, Lasho T. Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post-autologous stem cell transplantation lenalidomide maintenance therapy. Am J Hematol. 2021; 96(5):E157-E162.","DOI":"10.1002\/ajh.26125"},{"key":"69781","doi-asserted-by":"crossref","unstructured":"Mouhieddine TH, Nzerem C, Redd R. Clinical outcomes and evolution of clonal hematopoiesis in patients with newly diagnosed multiple myeloma. Cancer Res Commun. 2023; 3(12):2560-2571.","DOI":"10.1158\/2767-9764.CRC-23-0093"},{"key":"69782","doi-asserted-by":"crossref","unstructured":"Gramegna D, Bertoli D, Cattaneo C. The role of clonal hematopoiesis as driver of therapy-related myeloid neoplasms after autologous stem cell transplantation. Ann Hematol. 2022; 101(6):1227-1237.","DOI":"10.1007\/s00277-022-04806-x"},{"key":"69783","doi-asserted-by":"crossref","unstructured":"Soerensen JF, Aggerholm A, Rosenberg CA. Clonal evolution in patients developing therapy-related myeloid neoplasms following autologous stem cell transplantation. Bone Marrow Transplant. 2022; 57(3):460-465.","DOI":"10.1038\/s41409-022-01567-z"},{"key":"69784","doi-asserted-by":"crossref","unstructured":"Soerensen JF, Aggerholm A, Kerndrup GB. Clonal hematopoiesis predicts development of therapy-related myeloid neoplasms post-autologous stem cell transplantation. Blood Adv. 2020; 4(5):885-892.","DOI":"10.1182\/bloodadvances.2019001157"},{"key":"69785","doi-asserted-by":"crossref","unstructured":"Slavin TP, Teh JB, Weitzel JN. Association between clonal hematopoiesis and late nonrelapse mortality after autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019; 25(12):2517-2521.","DOI":"10.1016\/j.bbmt.2019.08.013"},{"key":"69786","doi-asserted-by":"crossref","unstructured":"Eskelund CW, Husby S, Favero F. Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL. Blood. 2020; 135(22):2000-2004.","DOI":"10.1182\/blood.2019003539"},{"key":"69787","doi-asserted-by":"crossref","unstructured":"Wong WH, Bhatt S, Trinkaus K. Engraftment of rare, pathogenic donor hematopoietic mutations in unrelated hematopoietic stem cell transplantation. Sci Transl Med. 2020; 12(526):eaax6249.","DOI":"10.1126\/scitranslmed.aax6249"},{"key":"69788","doi-asserted-by":"crossref","unstructured":"Gibson CJ, Kim HT, Zhao L. Donor clonal hematopoiesis and recipient outcomes after transplantation. J Clin Oncol. 2022; 40(2):189-201.","DOI":"10.52843\/cassyni.63p1c5"},{"key":"69789","doi-asserted-by":"crossref","unstructured":"Kim KH, Kim T, Novitzky-Basso I. Clonal hematopoiesis in the donor does not adversely affect long-term outcomes following allogeneic hematopoietic stem cell transplantation: result from a 13-year follow-up. Haematologica. 2023; 108(7):1817-1826.","DOI":"10.3324\/haematol.2022.281806"},{"key":"69790","doi-asserted-by":"crossref","unstructured":"Heumuller A, Wehrle J, Stosch J. Clonal hematopoiesis of indeterminate potential in older patients having received an allogeneic stem cell transplantation from young donors. Bone Marrow Transplant. 2020; 55(3):665-668.","DOI":"10.1038\/s41409-019-0575-4"},{"key":"69791","doi-asserted-by":"crossref","unstructured":"Frick M, Chan W, Arends CM. Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2019; 37(5):375-385.","DOI":"10.1200\/JCO.2018.79.2184"},{"key":"69792","doi-asserted-by":"crossref","unstructured":"Boettcher S, Wilk CM, Singer J. Clonal hematopoiesis in donors and long-term survivors of related allogeneic hematopoietic stem cell transplantation. Blood. 2020; 135(18):1548-1559.","DOI":"10.1182\/blood.2019003079"},{"key":"69793","doi-asserted-by":"crossref","unstructured":"Barrett AJ, Battiwalla M. Relapse after allogeneic stem cell transplantation. Expert Rev Hematol. 2010; 3(4):429-441.","DOI":"10.1586\/ehm.10.32"},{"key":"69794","doi-asserted-by":"crossref","unstructured":"Grimm J, Bill M, Jentzsch M. Clinical impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic transplantation. Bone Marrow Transplant. 2019; 54(8):1189-1197.","DOI":"10.1038\/s41409-018-0413-0"},{"key":"69795","doi-asserted-by":"crossref","unstructured":"Newell LF, Williams T, Liu J. Engrafted donor-derived clonal hematopoiesis after allogenic hematopoietic cell transplantation is associated with chronic graft-versus-host disease requiring immunosuppressive therapy, but no adverse impact on overall survival or relapse. Transplant Cell Ther. 2021; 27(8):662e661-662.","DOI":"10.1016\/j.jtct.2021.04.014"},{"key":"69796","doi-asserted-by":"crossref","unstructured":"Oran B, Champlin RE, Wang F. Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia. 2022; 36(1):257-262.","DOI":"10.1038\/s41375-021-01312-3"},{"key":"69797","doi-asserted-by":"crossref","unstructured":"Gillis N, Padron E, Wang T. Pilot study of donor-engrafted clonal hematopoiesis evolution and clinical outcomes in allogeneic hematopoietic cell transplantation recipients using a national registry. Transplant Cell Ther. 2023; 29(10):640e641-640.","DOI":"10.1016\/j.jtct.2023.07.021"},{"key":"69798","doi-asserted-by":"crossref","unstructured":"Imus PH, Pasca S, Tsai HL. Recipient clonal hematopoiesis in allogeneic bone marrow transplantation for lymphoid malignancies. Blood Adv. 2024; 8(14):3849-3858.","DOI":"10.1182\/bloodadvances.2023011761"},{"key":"69799","doi-asserted-by":"crossref","unstructured":"Tanaka T, Morita K, Loghavi S. Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia. Blood. 2021; 138(18):1733-1739.","DOI":"10.1182\/blood.2020010483"},{"key":"69800","doi-asserted-by":"crossref","unstructured":"Pidala J, Kim J, Anasetti C. The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality. Haematologica. 2011; 96(11):1678-1684.","DOI":"10.3324\/haematol.2011.049841"},{"key":"69801","doi-asserted-by":"crossref","unstructured":"Malard F, Holler E, Sandmaier BM, Huang H, Mohty M. Acute graft-versus-host disease. Nat Rev Dis Primers. 2023; 9(1):27.","DOI":"10.1038\/s41572-023-00438-1"},{"key":"69802","doi-asserted-by":"crossref","unstructured":"Fuster JJ, MacLauchlan S, Zuriaga MA. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017; 355(6327):842-847.","DOI":"10.1126\/science.aag1381"},{"key":"69803","doi-asserted-by":"crossref","unstructured":"Diamond B, Ziccheddu B, Maclachlan K. Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures. Blood. 2023; 141(19):2359-2371.","DOI":"10.1182\/blood.2022018244"},{"key":"69804","doi-asserted-by":"crossref","unstructured":"Bolanos-Meade J, Hamadani M, Wu J. Posttransplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023; 388(25):2338-2348.","DOI":"10.1056\/NEJMoa2215943"},{"key":"69805","doi-asserted-by":"crossref","unstructured":"Khoury JD, Solary E, Abla O. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022; 36(7):1703-1719.","DOI":"10.1038\/s41375-022-01613-1"},{"key":"69806","doi-asserted-by":"crossref","unstructured":"Bick AG, Weinstock JS, Nandakumar SK. Inherited causes of clonal haematopoiesis in 97,691 whole genomes. Nature. 2020; 586(7831):763-768.","DOI":"10.1038\/s41586-020-2819-2"},{"key":"69807","doi-asserted-by":"crossref","unstructured":"Patel DA, Schroeder MA, Choi J, DiPersio JF. Mouse models of graft-versus-host disease. Methods Cell Biol. 2022; 168:41-66.","DOI":"10.1016\/bs.mcb.2021.12.008"},{"key":"69808","doi-asserted-by":"crossref","unstructured":"Park E, Evans MA, Doviak H. Bone marrow transplantation procedures in mice to study clonal hematopoiesis. J Vis Exp. 2021; 26(171):e61875.","DOI":"10.3791\/61875"},{"key":"69809","doi-asserted-by":"crossref","unstructured":"Rhee JW, Pillai R, He T. Clonal hematopoiesis and cardiovascular disease in patients with multiple myeloma undergoing hematopoietic cell transplant. JAMA Cardiol. 2024; 9(1):16-24.","DOI":"10.1001\/jamacardio.2023.4105"},{"key":"69810","doi-asserted-by":"crossref","unstructured":"Lueck C, Panagiota V, Dammann E. Increased late noncardiac nonrelapse mortality in patients with atrial fibrillation diagnosed during their hospital stay for allogeneic stem cell transplantation. Transplant Cell Ther. 2022; 28(9):609.","DOI":"10.1016\/j.jtct.2022.06.010"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285392\/77139","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285392\/77833","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11658\/77139","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:06:42Z","timestamp":1794046002000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2024.285392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,20]]},"references-count":66,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.285392","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,20]]}}}